Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Yue-E Wu, Jing Cao, Li Wang, Ying-Ji Wei, Hui-Xin Liu, et al.
**BACKGROUND:** Spinal tuberculosis is the most common form of osteoarticular infection, with recommended anti-tuberculosis treatment durations typically being long (9-18 months), even for mild cases, increasing the risks of drug resistance, toxicity, and poor patient adhere…
Kou Y, Wan M, Shi W, Liu J, Zhao Z, et al.
…of the homologous and heterologous prime-boost immunization regimens of these two viral vector-based vaccines remains unclear. In the present study, we constructed recombinant Ad and MVA expressing an Ag85B-TB10.4 fusion protein (AdH4 and MVAH4) and evaluated the impact of their …
Feng Sun, Yang Li, Yilin Zhang, Cui Cai, Yuanyuan Chen, et al.
**OBJECTIVES:** Despite advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen. **METHO…
Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, et al.
…n. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017. Methods This retrospective cohort study included patients treated for multidrug-resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 …
Trébucq A, Decroo T, Van Deun A, Piubello A, Chiang CY, et al.
…ug-resistant tuberculosis (MDR-TB) treatment. Similar short regimens were studied in different settings, relying for their efficacy on a later generation fluoroquinolone, either gatifloxacin, moxifloxacin, or levofloxacin. We review the published material on short MDR-TB regimens…
Zhang Y, Zhu H, Fu L, Wang B, Guo S, et al.
…mine in in vitro and animal experiments. To identify potent regimens containing TBI-166 in TB chemotherapy, TBI-166 was assessed for pharmacological interactions in vitro and in vivo with several anti-TB drugs, including isoniazid (INH), rifampin (RFP), bedaquiline (BDQ), pretoma…
Weng T, Sun F, Li Y, Chen J, Chen X, et al.
… to treat, pressing more effective and innovative treatment regimens. New efficient regimens for MDR-TB have obtained high treatment success rates. However, those regimens without drug susceptibility testing (DST) are also likely to contribute to the emergence of resistance. Prec…
Rais M, Abdelaal H, Reese VA, Ferede D, Larsen SE, et al.
…me/boost regimen. More significantly, among all the vaccine regimens tested only repRNA-ID91/ID91+GLA-SE induced IFN-γ and TNF-secreting CD8 + T cells. Furthermore, the repRNA-ID91/ID91+GLA-SE vaccine strategy elicited high systemic proinflammatory cytokine responses and induced …
Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, et al.
…ic response surface (PRS) platform, we have identified drug regimens that treat tuberculosis more rapidly in mice than the current Standard Regimen used in humans. We show that PRS Regimen III, comprising clofazimine, SQ109, bedaquiline and pyrazinamide, rapidly sterilizes the lu…
James LP, Klaassen F, Sweeney S, Furin J, Franke MF, et al.
…ging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxa…
Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, et al.
… medical patient costs were negligible across all treatment regimens, while direct non-medical patient and guardian costs for travel, food and nutritional supplementation accounted for the largest proportion of total costs ($54.6, $227.8 and $224.3 for BPaL, the SSOR and SLOR res…
Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, et al.
Background and aims Multi drug or rifampicin resistant tuberculosis (MDR/RR-TB) is a major burden to TB prevention and eradication globally. Since 2016, WHO guidelines have included options for treating MDR/RR-TB with a standard regimen of 9 to 11 months duration (the 'shorter re…
Strydom N, van Wijk RC, Wang Q, Ernest JP, Chaba L, et al.
…g discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments. Using published treatment efficacy data from a mouse tubercu…
Lotz JK, Porter J, Conradie H, Boyles T, Gaunt B, et al.
… study describes outcomes in short and long DR-TB treatment regimens, over 5 years, at two rural treatment sites in SA. Characteristics were analysed for outcome correlates using multivariable logistic regression models. Results Of 282 treatment episodes, 62% were successful, wit…
Fu L, Zhang X, Xiong J, Sun F, Weng T, et al.
Objectives Long, ineffective, and toxic regimens hinder the treatment of patients with multidrug-resistant tuberculosis (MDR-TB) and pre-extensive drug-resistant tuberculosis (pre-XDR-TB). Methods We conducted a multicenter cohort study to prospectively evaluate the safety and ef…
Rosu L, Madan J, Worrall E, Tomeny E, Squire B
…rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health system. STRE…
Silva DR, Mello FCQ, Migliori GB
…iven the global burden of tuberculosis, shortened treatment regimens with existing or repurposed drugs are needed to contribute to tuberculosis control. The long duration of treatment of drug-susceptible tuberculosis (DS-TB) is associated with nonadherence and loss to follow up, …
Tsang CA, Shah N, Armstrong LR, Marks SM
Background In 2016, the World Health Organization (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the conventional 18-24 month regimen) for patients without extrapulmonary TB, pregnancy, a previous second-line T…
Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, et al.
…of long-acting bedaquiline and 2 ) evaluate the activity of regimens comprised of long-acting bedaquiline plus short (2-4 wk) oral companion courses of bedaquiline, with or without rifapentine, using the validated mouse model of tuberculosis preventive therapy. Methods: After the…
Du Y, Qiu C, Chen X, Wang J, Jing W, et al.
Background The emergence of multidrug-resistant tuberculosis (MDR-TB) poses a serious obstacle to global TB control programs. Methods We carried out a prospective, randomized, multicenter study in China that was focused on the potential of a shorter regimen containing clofazimine…
Villa S, Ferrarese M, Sotgiu G, Castellotti PF, Saderi L, et al.
…either isoniazid (INH) alone or rifampicin (RIF)-containing regimens. This study aims to assess and compare PT completion rates, the occurrence of adverse events, and the time of dropout among those receiving INH-alone or RIF-containing regimens at Villa Marelli Institute, Milan,…
Aruldhas BW, Hoglund RM, Ranjalkar J, Tarning J, Mathew SK, et al.
…drug levels in children with the currently available dosing regimens. This study attempted to investigate the pharmacokinetics of isoniazid and rifampicin, when used in children, and to optimize their dosing regimens. Methods Data were collected from 41 children, aged 2-16 years,…
Jason E Cummings, Lisa Woolhiser, Barbara Graham, Gregory T Robertson, M Nurul Islam, et al.
…ls is essential for optimizing and prioritizing therapeutic regimens. However, standardized classification methods for comparing high-performing regimens are currently lacking. This study defines a quantitative framework utilizing rifampicin-based regimens in a high-burden aeroso…
Setyawan MF, Mertaniasih NM, Soedarsono S
Background The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in th…
Kendall EA, Malhotra S, Cook-Scalise S, Denkinger CM, Dowdy DW
Background Regimens that could treat both rifampin-resistant (RR) and rifampin-susceptible tuberculosis (TB) while shortening the treatment duration have reached late-stage clinical trials. Decisions about whether and how to implement such regimens will require an understanding o…